Inflammation and anaemia in a broad spectrum of patients with heart failure

Heart

Volumn 98, Issue 16, 2012, Pages 1237-1241

  Kleijn, Lennaert ^a   Belonje, Anne M S ^a   Voors, Adriaan A ^a   De Boer, Rudolf A ^a   Jaarsma, Tiny ^a   Ghosh, Sudip ^b   Kim, Joseph ^b   Hillege, Hans L ^a   Van Gilst, Wiek H ^a   Van Veldhuisen, Dirk J ^a   Van Der Meer, Peter ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b AMGEN LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; ERYTHROPOIETIN; INTERLEUKIN 6; PEGSUNERCEPT; TUMOR NECROSIS FACTOR RECEPTOR 1;

AGED; ANEMIA; ARTICLE; BIOTINYLATION; CELL DIFFERENTIATION; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION;

AGED; AGED, 80 AND OVER; ANEMIA; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; ERYTHROPOIETIN; FEMALE; HEART FAILURE; HEMATOCRIT; HEMOGLOBINS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MULTIVARIATE ANALYSIS; NETHERLANDS; ODDS RATIO; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84864352214     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-301954     Document Type: Article

References (40)

1. Groenveld HF, Januzzi JL, Damman K, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008;52:818-27.
2. van der Meer P, van Veldhuisen DJ. Anaemia and renal dysfunction in chronic heart failure. Heart 2009;95:1808-12.
3. van der Meer P, Lok DJ, Januzzi JL, et al. Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. Eur Heart J 2008;29:1510-15. (Pubitemid 351881986)
4. Opasich C, Cazzola M, Scelsi L, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 2005;26:2232-7. (Pubitemid 41541385)
5. Westenbrink BD, Visser FW, Voors AA, et al. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J 2007;28:166-71.
6. van der Meer P, Lipsic E, Westenbrink BD, et al. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation 2005;112:1743-7. (Pubitemid 41368150)
7. Anand IS. Heart failure and anemia: mechanisms and pathophysiology. Heart Fail Rev 2008;13:379-86.
8. Silverberg DS, Wexler D, Iaina A, et al. The role of correction of anaemia in patients with congestive heart failure: a short review. Eur J Heart Fail 2008;10:819-23.
9. van Veldhuisen DJ, Anker SD, Ponikowski P, et al. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol 2011;8:485-93.
10. Khan W, Deepak SM, Coppinger T, et al. Beta blocker treatment is associated with improvement in renal function and anaemia in patients with heart failure. Heart 2006;92:1856-7. (Pubitemid 44851343)
11. Westenbrink BD, Voors AA, de Boer RA, et al. Bone marrow dysfunction in chronic heart failure patients. Eur J Heart Fail 2010;12:676-84.
12. Tang YD, Katz SD. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 2006;113:2454-61. (Pubitemid 43948053)
13. Belonje AM, Voors AA, van der Meer P, et al. Endogenous erythropoietin and outcome in heart failure. Circulation 2010;121:245-51.
14. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 1998;18:555-9. (Pubitemid 28391581)
15. Iversen PO, Andersson KB, Finsen AV, et al. Separate mechanisms cause anemia in ischemic vs. nonischemic murine heart failure. Am J Physiol Regul Integr Comp Physiol 2010;298:R808-14.
16. Iversen PO, Woldbaek PR, Tonnessen T, et al. Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am J Physiol Regul Integr Comp Physiol 2002;282:R166-72. (Pubitemid 34663923)
17. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-23.
18. Dunlay SM, Weston SA, Redfield MM, et al. Tumor necrosis factor-alpha and mortality in heart failure: a community study. Circulation 2008;118:625-31.
19. Morelli S, Di Girolamo F, Angelino A, et al. Anaemia as an inflammation-mediated condition during chronic heart failure. Possible role of fibrinogen. Acta Cardiol 2008;63:565-70.
20. Ferrari R, Bachetti T, Confortini R, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995;92:1479-86.
21. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000;102:3060-7.
22. Tousoulis D, Antoniades C, Stefanadis C. Assessing inflammatory status in cardiovascular disease. Heart 2007;93:1001-7. (Pubitemid 47122060)
23. Jaarsma T, van der Wal MH, Lesman-Leegte I, et al. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch Intern Med 2008;168:316-24. (Pubitemid 351281679)
24. Jaarsma T, Van Der Wal MH, Hogenhuis J, et al. Design and methodology of the COACH study: a multicenter randomised Coordinating study evaluating outcomes of advising and counselling in heart failure. Eur J Heart Fail 2004;6:227-33. (Pubitemid 38249367)
25. Smilde TD, van Veldhuisen DJ, Navis G, et al. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 2006;114:1572-80. (Pubitemid 44547427)
26. World Health Organization. Nutritional Anaemias: Report of a WHO Scientific Group. Geneva: World Health Organization, 1968.
27. Benson EW, Hardy R, Chaffin C, et al. New automated chemiluminescent assay for erythropoietin. J Clin Lab Anal 2000;14:271-3.
28. Grigorian Shamagian L, Varela Roman A, Garcia-Acuna JM, et al. Anaemia is associated with higher mortality among patients with heart failure with preserved systolic function. Heart 2006;92:780-4. (Pubitemid 43799211)
29. Go AS, Yang J, Ackerson LM, et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation 2006;113:2713-23. (Pubitemid 43947989)
30. Komajda M, Anker SD, Charlesworth A, et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J 2006;27:1440-6. (Pubitemid 43998078)
31. Anker SD, Voors A, Okonko D, et al. Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. Eur Heart J 2009;30:1331-9.
32. McMurray JJ, Carson PE, Komajda M, et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail 2008;10:149-56. (Pubitemid 351227428)
33. O'Meara E, Clayton T, McEntegart MB, et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation 2006;113:986-94. (Pubitemid 43879474)
34. Adlbrecht C, Kommata S, Hulsmann M, et al. Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body's red cell volume. Eur Heart J 2008;29:2343-50.
35. Damman K, Jaarsma T, Voors AA, et al. Both in- and out-hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH). Eur J Heart Fail 2009;11:847-54.
36. Avni T, Leibovici L, Gafter-Gvili A. Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis. Eur J Heart Fail 2012;14:423-9.
37. Grell M, Douni E, Wajant H, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995;83:793-802.
38. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008;358:2148-59.
39. Maciejewski JP, Selleri C, Sato T, et al. Nitric oxide suppression of human hematopoiesis in vitro. Contribution to inhibitory action of interferon-gamma and tumor necrosis factor-alpha. J Clin Invest 1995;96:1085-92.
40. Means RT Jr. Pathogenesis of the anemia of chronic disease: a cytokine-mediated anemia. Stem Cells 1995;13:32-7.